(Q46942850)

26 December 2017

title

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure (English)

1 reference

26 December 2017

1 reference

chronic heart failure

1 reference

John McMurray

3

0 references

author name string

Alison Seed

1

1 reference

26 December 2017

Roy Gardner

2

1 reference

26 December 2017

Chris Hillier

4

1 reference

26 December 2017

David Murdoch

5

1 reference

26 December 2017

Robert MacFadyen

6

1 reference

26 December 2017

Alain Bobillier

7

1 reference

26 December 2017

Jessica Mann

8

1 reference

26 December 2017

Theresa McDonagh

9

1 reference

26 December 2017

publication date

18 October 2007

1 reference

26 December 2017

European Journal of Heart Failure

published in

1 reference

26 December 2017

volume

9

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

1120-1127

1 reference

26 December 2017

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.09.002

10.1016/J.EJHEART.2007.09.002

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/372lvzim5ner3hjza4z7usnjza

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_372lvzim5ner3hjza4z7usnjza

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/372lvzim5ner3hjza4z7usnjza

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/372lvzim5ner3hjza4z7usnjza

1 reference